MBI gears up for Phase II trials of FSO69:
This article was originally published in Clinica
Molecular Biosystems (US) plans to begin Phase II trials of its organ perfusion ultrasound contrast agent, FSO69, in the autumn following the successful completion of Phase I trials. Left ventricular border enhancement and myocardial perfusion were observed in all subjects in the initial trial, says MBI. Safety of the second generation agent has been demonstrated, says chairman and CEO Kenneth Widder. "Future clinical studies will be performed to verify efficacy in the liver and kidneys."
You may also be interested in...
Senate Finance Committee’s approach to penalize companies for raising WAC list prices is not a ‘price control,’ but a reasonable approach to change the incentives that distort pricing in the supply chain, US HHS Secretary Alex Azar says.
With the pre-GDUFA backlog largely acted upon, the FDA expects ANDA approvals to decrease, but supplement actions to increase in FY 2020 and FY 2021.
February and March inspections deferred unless any are deemed mission critical. China director remains behind as staff evacuate.